VelocImmune technology
E579613
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
All labels observed (1)
| Label | Occurrences |
|---|---|
| VelocImmune technology canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6251195 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: VelocImmune technology Context triple: [Regeneron Pharmaceuticals, knownFor, VelocImmune technology]
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
-
C.
StaR technology
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
-
D.
Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company that develops novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform, with a focus on targeted treatments for cancer and other serious diseases.
-
E.
human adenovirus serotype 26 (Ad26)
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: VelocImmune technology Target entity description: VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
-
C.
StaR technology
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
-
D.
Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company that develops novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform, with a focus on targeted treatments for cancer and other serious diseases.
-
E.
human adenovirus serotype 26 (Ad26)
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
- F. None of above. chosen
Statements (39)
| Predicate | Object |
|---|---|
| instanceOf |
Regeneron proprietary technology
ⓘ
antibody discovery platform ⓘ biotechnology platform ⓘ |
| advantage |
high diversity of antibody repertoires
ⓘ
reduced risk of immunogenicity compared with chimeric antibodies ⓘ shortened timelines for antibody discovery ⓘ |
| appliedIn |
immunology drug development
ⓘ
infectious disease therapeutics ⓘ oncology drug development ⓘ rare disease therapeutics ⓘ |
| basedOn | genetically engineered mice ⓘ |
| commercialUse |
internal Regeneron drug pipeline
ⓘ
strategic collaborations with other pharmaceutical companies ⓘ |
| componentOf | Regeneron antibody discovery and development platform NERFINISHED ⓘ |
| developer | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| enables |
in vivo affinity maturation
ⓘ
rapid antibody generation ⓘ |
| field |
biopharmaceuticals
ⓘ
immunology ⓘ therapeutic antibody engineering ⓘ |
| hasKeyFeature |
human immunoglobulin gene loci inserted into mouse genome
ⓘ
inactivation of mouse immunoglobulin genes ⓘ |
| intellectualPropertyStatus | patented technology ⓘ |
| notableProductAssociation |
REGN-COV2 antibody cocktail
NERFINISHED
ⓘ
dupilumab NERFINISHED ⓘ other Regeneron monoclonal antibody therapeutics ⓘ |
| owner | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| produces | fully human monoclonal antibodies ⓘ |
| relatedTo |
Regeneron VelociSuite
NERFINISHED
ⓘ
VelociGene NERFINISHED ⓘ VelociMouse NERFINISHED ⓘ |
| supports |
clinical candidate selection
ⓘ
generation of antibody combinations ⓘ |
| technologyType |
in vivo antibody discovery system
ⓘ
transgenic animal platform ⓘ |
| usedFor |
generation of fully human monoclonal antibodies
ⓘ
preclinical drug development ⓘ therapeutic antibody discovery ⓘ |
| usesOrganism | transgenic mice ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: VelocImmune technology Description of subject: VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.